Log in
Enquire now
‌

US Patent 11578427 Designed ankyrin repeat domains with altered surface residues

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Molecular Partners
Molecular Partners
0
Current Assignee
Molecular Partners
Molecular Partners
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
115784270
Date of Patent
February 14, 2023
0
Patent Application Number
174004710
Date Filed
August 12, 2021
0
Patent Citations
‌
US Patent 10370414 Binding proteins comprising at least two repeat domains against HER2
‌
US Patent 10717772 Recombinant binding proteins targeting HER2 and serum albumin, and their uses
0
Patent Primary Examiner
‌
Anand U Desai
0

The present invention relates to designed ankyrin repeat domains with altered surface residues, as well as to proteins comprising such a designed ankyrin repeat domain, nucleic acids encoding such domains or proteins, methods of preparing such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11578427 Designed ankyrin repeat domains with altered surface residues

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.